Background: This study aimed to investigate the serum levels of mucoprotein 3 in hypertensive diseases of pregnancy.
Methods: In total, 60 consecutive women with gestational hypertensive diseases (gestational hypertension ( = 20), severe preeclampsia ( = 20), HELLP syndrome ( = 20)) and 20 pregnant women without any gestational hypertensive diseases were included for this prospective controlled study. Serum MUC3 protein levels were measured with commercially available ELISA kits.
Results: Serum MUC3 protein level was the lowest in normal pregnant women (0.1047 ± 0.0295 ng/ml); while the severity of the disease increases, it significantly increased in severe preeclampsia (0.2700 ± 0.0199 ng/mL) and HELLP syndrome group (0.3494 ± 0.0455 ng/mL), but less in the gestational hypertension (0.2172 ± 0.0354 ng/mL) group. Mean serum MUC3 protein level differences were found the least in gestational hypertension (0.1125 ± 0.0107, < 0.001), the most in HELLP syndrome (-0.2546 ± 0.0107, < 0.001) compared with the pregnant control group.
Conclusion: The increase in serum MUC3 protein concentration in these women supported the argument that serum MUC3 protein may be used as a marker indicating the severity of the gestational hypertensive diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732153 | PMC |
| http://dx.doi.org/10.1007/s13224-022-01677-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum MUC3 Protein as a Novel Marker of Gestational Hypertensive Disorders.
J Obstet Gynaecol India
December 2022
Department of Obstetrics and Gynecology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Background: This study aimed to investigate the serum levels of mucoprotein 3 in hypertensive diseases of pregnancy.
Methods: In total, 60 consecutive women with gestational hypertensive diseases (gestational hypertension ( = 20), severe preeclampsia ( = 20), HELLP syndrome ( = 20)) and 20 pregnant women without any gestational hypertensive diseases were included for this prospective controlled study. Serum MUC3 protein levels were measured with commercially available ELISA kits.
[Effect of fecal microbiota transplantation on type 1 diabetes mellitus in non-obese diabetic mice and its underlying mechanism].
Zhonghua Yi Xue Za Zhi
April 2022
Department of Endocrinology, Sir Run Run Hospital Affiliated to Nanjing Medical University,Nanjing 211166,China.
To investigate the effects of fecal microbiota transplantation (FMT) on non-obese diabetic (NOD) mice of type 1 diabetes mellitus (T1DM) and its underlying mechanisms. A total of 8-9 week-female NOD mice were randomly divided into control (=36) and FMT groups (=36) according to the random number table. Fecal microbiota from C57BL/6 mice were transplanted into FMT group, and control group were transplanted with microbiota from themselves, once every two days for 5 times.
View Article and Find Full Text PDFCereal Vinegar Sediment Alleviates Spontaneous Ulcerative Colitis in Il-10 Deficient Mice.
Mol Nutr Food Res
December 2021
National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, Jiangsu, 214122, P. R. China.
Scope: Cereal vinegar sediment (CVS) is precipitation generated during the preservation of vinegar. It has various functions such as anti-inflammatory, anti-tumor, hypoglycemic, and hypolipidemic. This study evaluates the effects of CVS on spontaneous colitis in Il-10 mice.
View Article and Find Full Text PDFMucins as a New Frontier in Pulmonary Fibrosis.
J Clin Med
September 2019
Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain.
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 3-5 years after diagnosis. Recent evidence identifies mucins as key effectors in cell growth and tissue remodeling processes compatible with the processes observed in IPF. Mucins are classified in two groups depending on whether they are secreted (secreted mucins) or tethered to cell membranes (transmembrane mucins).
View Article and Find Full Text PDFMapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Mol Cancer
November 2013
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA.
Background: PAM4, an antibody that has high specificity for pancreatic ductal adenocarcinoma (PDAC), compared to normal pancreas, benign lesions of the pancreas, and cancers originating from other tissues, is being investigated as a biomarker for early detection, as well as antibody-targeted imaging and therapy. Therefore, the identity of the antigen bound by this monoclonal antibody (MAb) can provide information leading to improved use of the antibody. Prior results suggested the antigen is a mucin-type glycoprotein rich in cysteine disulfide bridges that provide stable conformation for the PAM4-epitope.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!